Aequus Pharmaceuticals and reVision Therapeutics will collaborate to develop a treatment for Stargardt disease, according to a press release.
In addition, the agreement grants Aequus the option to acquire the North American commercial rights to REV-0100 from reVision.
“We believe that the existing efficacy data in animal models of Stargardt disease and established safety profile of the REV-0100 drug substance provide real hope for Stargardt disease patients who presently have no approved therapeutic options,” Paul Fehlner, co-founder and president of reVision Therapeutics, said in